109 related articles for article (PubMed ID: 32585335)
1. Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
Tabrizi S; Alshalalfa M; Mahal BA; Davicioni E; Liu Y; Mouw KW; Feng F; Nguyen PL; Muralidhar V
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):936-940. PubMed ID: 32585335
[TBL] [Abstract][Full Text] [Related]
2. Molecular events in neuroendocrine prostate cancer development.
Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.
Alshalalfa M; Nguyen PL; Beltran H; Chen WS; Davicioni E; Zhao SG; Rebbeck TR; Schaeffer EM; Lotan TL; Feng FY; Mahal BA
Eur Urol Oncol; 2019 Jul; 2(4):405-412. PubMed ID: 31164324
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
Su Y; Liu Y; Behrens CR; Bidlingmaier S; Lee NK; Aggarwal R; Sherbenou DW; Burlingame AL; Hann BC; Simko JP; Premasekharan G; Paris PL; Shuman MA; Seo Y; Small EJ; Liu B
JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185663
[TBL] [Abstract][Full Text] [Related]
5. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
[TBL] [Abstract][Full Text] [Related]
6. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of doublecortin (DCX) in pituitary adenoma.
Liu X; Ma L; Wang Z; Ye J; Liu X; Jiang G; Wang H
Bull Cancer; 2019 Dec; 106(12):1080-1085. PubMed ID: 31376915
[TBL] [Abstract][Full Text] [Related]
8. Influence of pathological factors on oncological outcomes after robot-assisted radical prostatectomy for localized prostate cancer: Results of a prospective study.
Kozal S; Peyronnet B; Cattarino S; Seisen T; Comperat E; Vaessen C; Mozer P; Renard-Penna R; Cussenot O; Rouprêt M; Drouin SJ
Urol Oncol; 2015 Jul; 33(7):330.e1-7. PubMed ID: 25998747
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a
Spratt DE; Alshalalfa M; Fishbane N; Weiner AB; Mehra R; Mahal BA; Lehrer J; Liu Y; Zhao SG; Speers C; Morgan TM; Dicker AP; Freedland SJ; Karnes RJ; Weinmann S; Davicioni E; Ross AE; Den RB; Nguyen PL; Feng FY; Lotan TL; Chinnaiyan AM; Schaeffer EM
Clin Cancer Res; 2019 Nov; 25(22):6721-6730. PubMed ID: 31515456
[TBL] [Abstract][Full Text] [Related]
10. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
11. Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS; Gupta RT; Healy P; McNamara M; Ramalingam S; Harrison M; George D; Zhang T; Wu Y; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):92-99. PubMed ID: 29230006
[TBL] [Abstract][Full Text] [Related]
12. Progenitors from the central nervous system drive neurogenesis in cancer.
Mauffrey P; Tchitchek N; Barroca V; Bemelmans AP; Firlej V; Allory Y; Roméo PH; Magnon C
Nature; 2019 May; 569(7758):672-678. PubMed ID: 31092925
[TBL] [Abstract][Full Text] [Related]
13. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.
Wang HT; Yao YH; Li BG; Tang Y; Chang JW; Zhang J
J Clin Oncol; 2014 Oct; 32(30):3383-90. PubMed ID: 25225419
[TBL] [Abstract][Full Text] [Related]
16. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma.
McWilliam LJ; Manson C; George NJ
Br J Urol; 1997 Aug; 80(2):287-90. PubMed ID: 9284204
[TBL] [Abstract][Full Text] [Related]
18. Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.
Hashimoto T; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Namiki K; Ohno Y
Int J Clin Oncol; 2020 Sep; 25(9):1704-1710. PubMed ID: 32500468
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
Kallakury BV; Sheehan CE; Ambros RA; Fisher HA; Kaufman RP; Ross JS
Cancer; 1997 Aug; 80(4):753-63. PubMed ID: 9264360
[TBL] [Abstract][Full Text] [Related]
20. De novo neuroendocrine features in prostate cancer.
Abdulfatah E; Fine SW; Lotan TL; Mehra R
Hum Pathol; 2022 Sep; 127():112-122. PubMed ID: 35810832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
